Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Assenagon Asset Management S.A.

Key Points

• Assenagon Asset Management reduced its Tarsus Pharmaceuticals stake by 26%, selling 332,699 shares and retaining 947,495 shares valued at approximately $59.6 million. Institutional investors collectively own 90.01% of Tarsus.
• Tarsus insiders also sold shares, including the CEO’s 10,000 shares and a director’s 12,500 shares; insiders sold 39,850 shares worth about $2.45 million over the past 90 days.
• Tarsus reported quarterly revenue of $173.9 million, ahead of expectations, but its loss of $0.43 per share was wider than the projected $0.19 loss. Shares opened at $64.79, while analysts maintain a “Moderate Buy” consensus with an average price target of $90.17.

Assenagon Asset Management S.A. cut its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 26.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 947,495 shares of the company's stock after selling 332,699 shares during the quarter. Assenagon Asset Management S.A. owned 2.20% of Tarsus Pharmaceuticals worth $59,635,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Tarsus Pharmaceuticals by 5.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,143 shares of the company's stock valued at $1,137,000 after buying an additional 1,217 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Tarsus Pharmaceuticals by 2.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,220 shares of the company's stock valued at $3,659,000 after buying an additional 1,394 shares in the last quarter. Jane Street Group LLC grew its stake in Tarsus Pharmaceuticals by 105.8% in the 1st quarter. Jane Street Group LLC now owns 10,456 shares of the company's stock valued at $537,000 after acquiring an additional 190,000 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Tarsus Pharmaceuticals by 402.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 140,610 shares of the company's stock valued at $5,696,000 after acquiring an additional 112,637 shares in the last quarter. Finally, Invesco Ltd. increased its holdings in Tarsus Pharmaceuticals by 12.3% during the 2nd quarter. Invesco Ltd. now owns 928,501 shares of the company's stock valued at $37,614,000 after acquiring an additional 101,978 shares in the last quarter. Institutional investors and hedge funds own 90.01% of the company's stock.

Insider Transactions at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 10,000 shares of the stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $61.55, for a total transaction of $615,500.00. Following the sale, the chief executive officer directly owned 847,991 shares of the company's stock, valued at approximately $52,193,846.05. This represents a 1.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director William J. Phd Link sold 12,500 shares of Tarsus Pharmaceuticals stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $62.12, for a total transaction of $776,500.00. Following the completion of the transaction, the director directly owned 106,786 shares of the company's stock, valued at $6,633,546.32. This trade represents a 10.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 39,850 shares of company stock worth $2,452,821. 9.64% of the stock is owned by corporate insiders.

Tarsus Pharmaceuticals Trading Down 0.8%

Shares of TARS opened at $64.79 on Friday. The stock has a 50-day moving average price of $61.39 and a 200 day moving average price of $64.94. Tarsus Pharmaceuticals, Inc. has a one year low of $47.21 and a one year high of $85.25. The company has a market capitalization of $2.79 billion, a P/E ratio of -59.44 and a beta of 0.53. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.71 and a current ratio of 3.74.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.24). The company had revenue of $173.91 million for the quarter, compared to analyst estimates of $169.65 million. Tarsus Pharmaceuticals had a negative return on equity of 13.57% and a negative net margin of 7.67%. Sell-side analysts forecast that Tarsus Pharmaceuticals, Inc. will post -1.27 EPS for the current fiscal year.

More Tarsus Pharmaceuticals News

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: XDEMVY sales continued to accelerate. Second-quarter net product sales reached $173.9 million, up more than 69% year over year and ahead of analysts’ expectations of approximately $169.7 million. The company projected 2026 XDEMVY net sales of $685 million to $705 million, supporting the investment case for its approved Demodex blepharitis treatment. Tarsus second-quarter results
• Positive Sentiment: Tarsus is expanding into a potentially significant retinal-disease market. The company agreed to acquire Alkeus Pharmaceuticals and its Phase 3-stage oral candidate gildeuretinol (ALK-001), which targets Stargardt disease. The transaction gives Tarsus a potential blockbuster opportunity in a disease with no FDA-approved therapy and broadens its pipeline beyond XDEMVY. Alkeus acquisition
• Neutral Sentiment: Analyst expectations remain above the current trading level. Recent price targets cited by Quiver Quantitative range from $88 to $105, with a $90 median target, although these targets may not yet fully reflect the Alkeus transaction or updated execution risks.
• Negative Sentiment: The quarterly loss was materially worse than expected. Tarsus reported a loss of $0.43 per share versus consensus estimates for a loss of roughly $0.19 to $0.21, despite revenue exceeding forecasts. The company remains unprofitable, which can increase sensitivity to spending and deal-related costs. Tarsus Q2 earnings report
• Negative Sentiment: The Alkeus deal and financing create near-term execution and dilution concerns. The acquisition has a potential value of up to $800 million, including $450 million in upfront consideration, while Tarsus separately announced a $125 million private placement. Investors may be concerned about capital needs, share dilution and the clinical and regulatory risks of ALK-001. Tarsus Alkeus acquisition announcement Tarsus private placement

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on TARS shares. Mizuho cut their price objective on Tarsus Pharmaceuticals from $100.00 to $98.00 and set an "outperform" rating for the company in a research report on Friday, July 31st. Wall Street Zen lowered Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Sunday, July 12th. Guggenheim cut their target price on shares of Tarsus Pharmaceuticals from $90.00 to $89.00 and set a "buy" rating for the company in a research note on Tuesday, July 21st. Oppenheimer initiated coverage on shares of Tarsus Pharmaceuticals in a research note on Friday, April 24th. They set an "outperform" rating and a $98.00 price target on the stock. Finally, HC Wainwright reissued a "buy" rating and issued a $88.00 price objective on shares of Tarsus Pharmaceuticals in a research report on Thursday, July 9th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $90.17.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company's research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus's lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source